Zhang Y, Duan D, Tian Q, Wang C, Wei S
Front Pharmacol. 2025; 15:1524903.
PMID: 39749203
PMC: 11694325.
DOI: 10.3389/fphar.2024.1524903.
Lim N, Lim S, Chung W
Adv Pharmacol Pharm Sci. 2024; 2024:6069151.
PMID: 39502577
PMC: 11537742.
DOI: 10.1155/2024/6069151.
Cimpeanu R, Salmen T, Boldeanu L, Mustata M, Fortofoiu D, Cazacu S
Curr Health Sci J. 2024; 50(2):256-266.
PMID: 39371064
PMC: 11447499.
DOI: 10.12865/CHSJ.50.02.11.
Sawaid I, Samson A
J Clin Med. 2024; 13(7).
PMID: 38610738
PMC: 11012754.
DOI: 10.3390/jcm13071970.
Nagao S, Yabuuchi Y, Tanaka K, Morihisa Y, Kobayashi T, Akiyama S
Intern Med. 2023; 63(14):2001-2010.
PMID: 38008447
PMC: 11309866.
DOI: 10.2169/internalmedicine.2857-23.
The central role of gastrin in gastric cancer.
Waldum H, Mjones P
Front Oncol. 2023; 13:1176673.
PMID: 37941554
PMC: 10628637.
DOI: 10.3389/fonc.2023.1176673.
Application of electron microscopy in gastroenterology.
Iwamuro M, Urata H, Tanaka T, Okada H
World J Gastrointest Pathophysiol. 2022; 13(2):41-49.
PMID: 35433095
PMC: 8976235.
DOI: 10.4291/wjgp.v13.i2.41.
The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease.
Kawaguchi K, Yashima K, Ikebuchi Y, Yoshida A, Kuwamoto S, Isomoto H
Intern Med. 2022; 61(17):2587-2592.
PMID: 35135919
PMC: 9492478.
DOI: 10.2169/internalmedicine.8701-21.
Gastritis, Gastric Polyps and Gastric Cancer.
Waldum H, Fossmark R
Int J Mol Sci. 2021; 22(12).
PMID: 34207192
PMC: 8234857.
DOI: 10.3390/ijms22126548.
Tumor Classification Should Be Based on Biology and Not Consensus: Re-Defining Tumors Based on Biology May Accelerate Progress, An Experience of Gastric Cancer.
Waldum H
Cancers (Basel). 2021; 13(13).
PMID: 34202596
PMC: 8269176.
DOI: 10.3390/cancers13133159.
Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells.
Waldum H, Mjones P
Cancers (Basel). 2020; 12(11).
PMID: 33266504
PMC: 7700139.
DOI: 10.3390/cancers12113477.
Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?.
McCarthy D
Int J Mol Sci. 2020; 21(2).
PMID: 31963924
PMC: 7014182.
DOI: 10.3390/ijms21020662.
Problems Associated with Deprescribing of Proton Pump Inhibitors.
Helgadottir H, Bjornsson E
Int J Mol Sci. 2019; 20(21).
PMID: 31684070
PMC: 6862638.
DOI: 10.3390/ijms20215469.
Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.
Lee L, Ramos-Alvarez I, Ito T, Jensen R
Int J Mol Sci. 2019; 20(20).
PMID: 31623145
PMC: 6829234.
DOI: 10.3390/ijms20205128.
Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test.
Miyamoto S, Tsuda M, Kato M, Mabe K, Muto S, Ono S
J Clin Biochem Nutr. 2019; 64(2):174-179.
PMID: 30936631
PMC: 6436034.
DOI: 10.3164/jcbn.18-75.
Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
Hughes J, Chiu D, Kalra P, Green D
PLoS One. 2018; 13(5):e0197400.
PMID: 29799851
PMC: 5969743.
DOI: 10.1371/journal.pone.0197400.
Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M
Eur J Clin Pharmacol. 2017; 74(1):45-52.
PMID: 28986609
DOI: 10.1007/s00228-017-2324-1.
Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy.
Anjiki H, Mukaisho K, Kadomoto Y, Doi H, Yoshikawa K, Nakayama T
Clin J Gastroenterol. 2017; 10(2):128-136.
PMID: 28160247
DOI: 10.1007/s12328-017-0714-7.
Gastrin and Gastric Cancer.
Waldum H, Sagatun L, Mjones P
Front Endocrinol (Lausanne). 2017; 8:1.
PMID: 28144230
PMC: 5239792.
DOI: 10.3389/fendo.2017.00001.
Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: A population-based nested case-control study.
Huang Y, Wu A, Chiou H, Chuang M, Meng T, Chien L
Oncotarget. 2016; 8(4):6642-6651.
PMID: 28036262
PMC: 5351659.
DOI: 10.18632/oncotarget.14254.